|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-8.87/-0.06
|
企業價值
7.64B
|
資產負債 |
每股賬面淨值
-4.53
|
現金流量 |
現金流量率
--
|
損益表 |
收益
266.72M
|
每股收益
2.84
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/17 01:24 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America. |